Oxford Immune Algorithmics is proud to announce the appointment of internationally recognised innovator, Dr. Corey Cutler, to its Scientific Advisory Board. Corey Cutler, MD, MPH, FRCP(C), is the Medical Director of the Stem Cell Transplantation Program at the Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School. As a clinical expert and innovator in the oncology field, Dr. Cutler brings to bear extensive experience from many perspectives and contributes significantly to Stem Cell Transplantation research. He has led several national efforts to assist the Centres for Medicare Services’ Coverage with Evidence Determination Program and the DF/HCC Cord Blood Program.
Dr. Cutler graduated from McGill University’s Faculty of Medicine, completed a residency in Internal Medicine at the McGill University Health Science Centre, and concluded fellowship training in haematology, medical oncology, and stem cell transplantation at the Dana-Farber Cancer Institute. Dr. Cutler earned an MPH degree at the Harvard School of Public Health and has contributed to more than 300 peer-reviewed publications and 40 reviews and book chapters.
His fields of expertise are numerous. Dr. Cutler is a stem cell transplantation physician, and a 20-year investigator and researcher involved in the development of innovative drug-based approaches for allogeneic stem cell transplantation, as an alternative to non-transplant therapies. As its Medical Director, he has administrative responsibilities overseeing the Stem Cell Transplantation Program. He also has several teaching positions with responsibility for teaching fellows in haematology/oncology at the DFCI and has served on various committees of the Centre for International Blood and Marrow Transplantation Research.
Dr. Cutler also has specific expertise in the prevention and treatment of acute and chronic graft-vs.-host-disease (GVHD) stemming from years in clinical practice, including developing innovative drug-based approaches for the prevention and treatment of acute and chronic GVHD. He also developed a strategy to prevent acute GVHD using the novel immunosuppressant, sirolimus. As a result, the regimen has now become the standard of care at several centres nationally and internationally. In addition, he conducted the largest prospective trial of the monoclonal anti-B cell antibody, rituximab, in chronic GVHD, whose compound is now considered standard-of-care therapy.
Oxford Immune Algorithmics warmly welcomes Dr. Cutler to its Scientific Advisory Board as it liberates individual healthcare through early disease detection and effective health management.
Oxford Immune Algorithmics (OIA) is an award-winning Bio-Tech company incubated by the University of Oxford with a vision to democratise healthcare to rid the world of preventable diseases. To do this, OIA harnesses the power of an advanced type of augmented AI that has human-like reasoning capabilities to monitor people’s immune systems. OIA operates multi-nationally to build technology that moves healthcare away from its reliance on population-wide symptom pattern matching toward value-based precision medicine and personalised diagnostics.